NASDAQ: ENDP |
| Healthcare / Drug Manufacturers / Ireland |
0.3831 | +0.0154 | +4.19% | Vol 19.94M | 1Y Perf -92.53% |
Jun 27th, 2022 16:00 DELAYED |
BID | 0.3810 | ASK | 0.3846 | ||
Open | 0.3933 | Previous Close | 0.3677 | ||
Pre-Market | - | After-Market | 0.39 | ||
- - | 0.01 1.80% |
Target Price | 2.25 | Analyst Rating | Moderate Sell 4.50 | |
Potential % | 487.31 | Finscreener Ranking | ★★★+ 52.30 | |
Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★+ 52.48 | |
Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★+ 54.41 | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
Price Range Ratio 52W % | 1.52 | Earnings Rating | Strong Sell | |
Market Cap | 85.47M | Earnings Date | 4th Aug 2022 | |
Alpha | -0.03 | Standard Deviation | 0.26 | |
Beta | 1.12 |
Today's Price Range 0.37500.4030 | 52W Range 0.28007.07 | 5 Year PE Ratio Range -1.1013.80 |
Summary:
Sell
Technical Indicators: | Neutral |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | 13.01% | ||
1 Month | -18.49% | ||
3 Months | -84.23% | ||
6 Months | -90.42% | ||
1 Year | -92.53% | ||
3 Years | -90.70% | ||
5 Years | -96.67% | ||
10 Years | -98.74% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 106.61 | |||
ROE last 12 Months | 77.45 | |||
ROA (5Y Avg) | -1.93 | |||
ROA last 12 Months | -8.47 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | - | |||
Return on invested Capital Q | - | |||
Return on invested Capital Y | - | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 5.70 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-0.10 | ||||
2.64 | ||||
0.03 | ||||
0.20 | ||||
0.30 | ||||
1.58 | ||||
-0.01 | ||||
-5.58 | ||||
6.78B | ||||
Forward PE | 1.26 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.40 | ||||
1.80 | ||||
- | ||||
- | ||||
-0.20 | ||||
Leverage Ratio | -9.20 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
59.40 | ||||
-3.40 | ||||
11.80 | ||||
-31.30 | ||||
-24.74 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
2.93B | ||||
12.45 | ||||
0.20 | ||||
-4.97 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q01 2022 | 0.44 | 0.66 | 50.00 |
Q04 2021 | 0.70 | 0.84 | 20.00 |
Q03 2021 | 0.46 | 0.80 | 73.91 |
Q02 2021 | 0.42 | 0.65 | 54.76 |
Q01 2021 | 0.48 | 0.73 | 52.08 |
Q04 2020 | 0.50 | 0.75 | 50.00 |
Q03 2020 | 0.14 | 0.52 | 271.43 |
Q02 2020 | 0.35 | 0.65 | 85.71 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | -0.15 | -131.92 | Negative |
9/2022 QR | 0.13 | -59.38 | Negative |
12/2022 FY | 0.79 | -51.23 | Negative |
12/2023 FY | 0.29 | -74.11 | Negative |
Next Report Date | 4th Aug 2022 |
Estimated EPS Next Report | -0.15 |
Estimates Count | 3 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 19.94M |
Shares Outstanding | 223.10K |
Shares Float | 168.86M |
Trades Count | 25.96K |
Dollar Volume | 7.74M |
Avg. Volume | 24.12M |
Avg. Weekly Volume | 31.26M |
Avg. Monthly Volume | 26.41M |
Avg. Quarterly Volume | 14.67M |
Endo International plc (NASDAQ: ENDP) stock closed at 0.3831 per share at the end of the most recent trading day (a 4.19% change compared to the prior day closing price) with a volume of 19.94M shares and market capitalization of 85.47M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 3397 people. Endo International plc CEO is Blaise Coleman.
The one-year performance of Endo International plc stock is -92.53%, while year-to-date (YTD) performance is -89.81%. ENDP stock has a five-year performance of -96.67%. Its 52-week range is between 0.28 and 7.0652, which gives ENDP stock a 52-week price range ratio of 1.52%
Endo International plc currently has a PE ratio of -0.10, a price-to-book (PB) ratio of 2.64, a price-to-sale (PS) ratio of 0.03, a price to cashflow ratio of 0.20, a PEG ratio of 2.32, a ROA of -8.47%, a ROC of -% and a ROE of 77.45%. The company’s profit margin is -24.74%, its EBITDA margin is 11.80%, and its revenue ttm is $2.93 Billion , which makes it $12.45 revenue per share.
Of the last four earnings reports from Endo International plc, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.15 for the next earnings report. Endo International plc’s next earnings report date is 04th Aug 2022.
The consensus rating of Wall Street analysts for Endo International plc is Moderate Sell (4.5), with a target price of $2.25, which is +487.31% compared to the current price. The earnings rating for Endo International plc stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Endo International plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Endo International plc has a Sell technical analysis rating based on Technical Indicators (ADX : 20.16, ATR14 : 0.09, CCI20 : -37.96, Chaikin Money Flow : -0.24, MACD : -0.20, Money Flow Index : 38.32, ROC : -16.43, RSI : 31.24, STOCH (14,3) : 30.45, STOCH RSI : 0.87, UO : 36.85, Williams %R : -69.55), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Endo International plc in the last 12-months were: Blaise A. Coleman (Option Excercise at a value of $0), Mark Bradley (Option Excercise at a value of $0), Matthew J. Maletta (Option Excercise at a value of $0), Patrick Barry (Option Excercise at a value of $0)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Sell | Moderate Sell | Moderate Sell |
After a string of acquisitions and divestitures, Endo is a specialty pharmaceutical company with a considerable presence in pain management. The acquisitions of Auxilium and Par increased the company's presence in urology and generics, respectively.
CEO: Blaise Coleman
Telephone: +353 12682000
Address: Simmonscourt Road, Ballsbridge, Dublin 4, , IE
Number of employees: 3 397
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.